4252-25-9 Usage
Property
Synthetic derivative of coumarin
Explanation: Phenprocoumon is a synthetic compound derived from coumarin, a natural substance found in certain plants.
Property
Potent anticoagulant drug
Explanation: Phenprocoumon is a powerful medication used to prevent and treat blood clots in conditions such as deep vein thrombosis and pulmonary embolism.
Property
Chemical structure containing two chloroethylamine groups
Explanation: The presence of two chloroethylamine groups in the chemical structure of phenprocoumon is responsible for its anticoagulant properties.
Property
Inhibits production of certain proteins involved in blood clotting
Explanation: Phenprocoumon works by interfering with the synthesis of specific proteins that are essential for the blood clotting process.
Property
Blocks synthesis of vitamin K-dependent clotting factors
Explanation: Phenprocoumon prevents the formation of blood clots by inhibiting the production of clotting factors that depend on vitamin K for their synthesis.
Property
Typically administered orally
Explanation: Phenprocoumon is usually taken by mouth.
Property
Long half-life allowing for once-daily dosing
Explanation: The extended half-life of phenprocoumon enables it to be taken just once a day.
Property
Requires careful monitoring and dose adjustment
Explanation: Due to its narrow therapeutic window and potential for interactions with other medications and foods, phenprocoumon needs to be closely monitored and its dosage adjusted as needed.
Check Digit Verification of cas no
The CAS Registry Mumber 4252-25-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,2,5 and 2 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 4252-25:
(6*4)+(5*2)+(4*5)+(3*2)+(2*2)+(1*5)=69
69 % 10 = 9
So 4252-25-9 is a valid CAS Registry Number.
InChI:InChI=1/C13H17Cl2NO2/c14-6-8-16(9-7-15)12-3-1-2-11(10-12)4-5-13(17)18/h1-3,10H,4-9H2,(H,17,18)
4252-25-9Relevant articles and documents
Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA
Fang, Kun,Dong, Guoqiang,Wang, Hongyu,He, Shipeng,Wu, Shanchao,Wang, Wei,Sheng, Chunquan
, p. 30 - 36 (2017/12/26)
Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.
